211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases. (1992)

Peer-Reviewed Study · Link EM; Carpenter RN · August 15, 1992

Link EM et al., 1992-08-15: Human melanoma xenograft study in nude mice using methylene blue labelled with the alpha-emitter astatine-211 (targeted radiotherapy, not photodynamic therapy): growth of the smallest pigmented lesions was completely inhibited for 65 days, while poorly pigmented tumours were inhibited for only 7 days.

Growth of the smallest HX118 lesions investigated was completely inhibited for 65 days, whereas the growth inhibition of HX34 tumors of the same size lasted 7 days only.

Link EM et al., 1992-08-15: Human melanoma xenograft study in nude mice using methylene blue labelled with the alpha-emitter astatine-211 (targeted radiotherapy, not photodynamic therapy): growth of the smallest pigmented lesions was completely inhibited for 65 days, while poorly pigmented tumours were inhibited for only 7 days. C5 Link 1992. Study type: in vivo human melanoma xenografts (HX118 pigmented, HX34 poorly pigmented) in nude mice. N: not stated in the abstract. Country: Australia (Australian Nuclear Science and Technology Organisation). Agent: 211At-methylene blue, 211At-MTB, injected intravenously, four doses. Mechanism: alpha-particle radiotherapy targeted by methylene blue's melanin affinity – NOT photodynamic therapy and NOT light-activated. Funder: 'Research Support, Non-U.S. Gov't'. Comparator: untreated control animals. PARTLY because growth arrest is real and long-lasting in pigmented tumours, but the effect comes from the radioisotope, and the same paper shows the effect depends on pigmentation and tumour size. Study type: animal.